View (Beijing, China)Pub Date : 2021-08-01Epub Date: 2021-05-05DOI: 10.1002/VIW.20200180
Chunxi Zeng, Xucheng Hou, Margaret Bohmer, Yizhou Dong
{"title":"Advances of nanomaterials-based strategies for fighting against COVID-19.","authors":"Chunxi Zeng, Xucheng Hou, Margaret Bohmer, Yizhou Dong","doi":"10.1002/VIW.20200180","DOIUrl":"10.1002/VIW.20200180","url":null,"abstract":"<p><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 100 million people globally due to its high infectivity. After decades of efforts on the studies of nanomaterials, researchers have applied nanomaterials-based strategies to combat the pandemic of the coronavirus disease 2019 (COVID-19). First, nanomaterials facilitate the development of easy, fast, and low-cost diagnostic assays to detect SARS-CoV-2 and related biomarkers. Second, nanomaterials enable the efficient delivery of viral antigens to antigen-presenting cells or serve as adjuvants in the host, leading to vaccine development at an unprecedented pace. Lastly, nanomaterials-based treatments may inhibit SARS-CoV-2 replication and reduce inflammation. Overall, nanomaterials have played important roles in controlling this COVID-19 pandemic. Here, we provide a brief overview of the representative examples of nanomaterials-based diagnostics, vaccines, and therapeutics in the fight against COVID-19.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"2 4","pages":"20200180"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39614726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
View (Beijing, China)Pub Date : 2021-08-01Epub Date: 2021-05-04DOI: 10.1002/VIW.20210003
Guozhen Liu, Cheng Jiang, Xiaoting Lin, Yang Yang
{"title":"Point-of-care detection of cytokines in cytokine storm management and beyond: Significance and challenges.","authors":"Guozhen Liu, Cheng Jiang, Xiaoting Lin, Yang Yang","doi":"10.1002/VIW.20210003","DOIUrl":"10.1002/VIW.20210003","url":null,"abstract":"<p><p>Cytokines are signaling molecules between cells in immune system. Cytokine storm, due to the sudden acute increase in levels of pro-inflammatory circulating cytokines, can result in disease severity and major-organ damage. Thus, there is urgent need to develop rapid, sensitive, and specific methods for monitoring of cytokines in biology and medicine. Undoubtedly, point-of-care testing (POCT) will provide clinical significance in disease early diagnosis, management, and prevention. This review aims to summarize and discuss the latest technologies for detection of cytokines with a focus on POCT. The overview of diseases resulting from imbalanced cytokine levels, such as COVID-19, sepsis and other cytokine release syndromes are presented. The clinical cut-off levels of cytokine as biomarkers for different diseases are summarized. The challenges and perspectives on the development of cytokine POCT devices are also proposed and discussed. Cytokine POCT devices are expected to be the ongoing spotlight of disease management and prevention during COVID-19 pandemic and also the post COVID-19 pandemic era.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"2 4","pages":"20210003"},"PeriodicalIF":0.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39614728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
View (Beijing, China)Pub Date : 2021-06-01Epub Date: 2021-03-09DOI: 10.1002/VIW.20200155
Mohd Ahmar Rauf, Munazzah Tasleem, Ketki Bhise, Katyayani Tatiparti, Samaresh Sau, Arun K Iyer
{"title":"Nano-therapeutic strategies to target coronavirus.","authors":"Mohd Ahmar Rauf, Munazzah Tasleem, Ketki Bhise, Katyayani Tatiparti, Samaresh Sau, Arun K Iyer","doi":"10.1002/VIW.20200155","DOIUrl":"10.1002/VIW.20200155","url":null,"abstract":"<p><p>The coronaviruses have caused severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS), and the more recent coronavirus pneumonia (COVID-19). The global COVID-19 pandemic requires urgent action to develop anti-virals, new therapeutics, and vaccines. In this review, we discuss potential therapeutics including human recombinant ACE2 soluble, inflammatory cytokine inhibitors, and direct anti-viral agents such as remdesivir and favipiravir, to limit their fatality. We also discuss the structure of the SARS-CoV-2, which is crucial to the timely development of therapeutics, and previous attempts to generate vaccines against SARS-CoV and MERS-CoV. Finally, we provide an overview of the role of nanotechnology in the development of therapeutics as well as in the diagnosis of the infection. This information is key for computational modeling and nanomedicine-based new therapeutics by counteracting the variable proteins in the virus. Further, we also try to effectively share the latest information about many different aspects of COVID-19 vaccine developments and possible management to further scientific endeavors.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"2 3","pages":"20200155"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/VIW.20200155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39614729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
View (Beijing, China)Pub Date : 2021-06-01Epub Date: 2021-01-31DOI: 10.1002/VIW.20200186
Kristen D Popowski, Phuong-Uyen C Dinh, Arianna George, Halle Lutz, Ke Cheng
{"title":"Exosome therapeutics for COVID-19 and respiratory viruses.","authors":"Kristen D Popowski, Phuong-Uyen C Dinh, Arianna George, Halle Lutz, Ke Cheng","doi":"10.1002/VIW.20200186","DOIUrl":"10.1002/VIW.20200186","url":null,"abstract":"<p><p>Respiratory viral diseases are a leading cause of mortality in humans. They have proven to drive pandemic risk due to their complex transmission factors and viral evolution. However, the slow production of effective antiviral drugs and vaccines allows for outbreaks of these diseases, emphasizing a critical need for refined antiviral therapeutics. The delivery of exosomes, a naturally secreted extracellular vesicle, yields therapeutic effects for a variety of diseases, including viral infection. Exosomes and viruses utilize similar endosomal sorting pathways and mechanisms, providing exosomes with the potential to serve as a therapeutic that can target, bind, and suppress cellular uptake of various viruses including the novel severe acute respiratory syndrome coronavirus 2. Here, we review the relationship between exosomes and respiratory viruses, describe potential exosome therapeutics for viral infections, and summarize progress toward clinical translation for lung-derived exosome therapeutics.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"2 3","pages":"20200186"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39614727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
View (Beijing, China)Pub Date : 2021-04-01Epub Date: 2021-01-01DOI: 10.1002/VIW.20200082
Chianru Tan, Dongdong Fan, Nan Wang, Fang Wang, Bo Wang, Lingxiang Zhu, Yong Guo
{"title":"Applications of digital PCR in COVID-19 pandemic.","authors":"Chianru Tan, Dongdong Fan, Nan Wang, Fang Wang, Bo Wang, Lingxiang Zhu, Yong Guo","doi":"10.1002/VIW.20200082","DOIUrl":"10.1002/VIW.20200082","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has led to a public health crisis and global panic. This infectious disease is caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Digital polymerase chain reaction (dPCR), which is an emerging nucleic acid amplification technology that allows absolute quantification of nucleic acids, plays an important role in the detection of SARS-CoV-2. In this review, we introduce the principle and advantages of dPCR, and review the applications of dPCR in the COVID-19 pandemic, including detection of low copy number viruses, measurement of the viral load, preparation of reference materials, monitoring of virus concentration in the environment, detection of viral mutations, and evaluation of anti-SARS-CoV-2 drugs. We also discuss the challenges of dPCR in clinical practice.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"2 2","pages":"20200082"},"PeriodicalIF":0.0,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39613854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qianyu Lin, Jason Y C Lim, Kun Xue, Pek Yin Michelle Yew, Cally Owh, Pei Lin Chee, Xian Jun Loh
{"title":"Sanitizing agents for virus inactivation and disinfection.","authors":"Qianyu Lin, Jason Y C Lim, Kun Xue, Pek Yin Michelle Yew, Cally Owh, Pei Lin Chee, Xian Jun Loh","doi":"10.1002/viw2.16","DOIUrl":"10.1002/viw2.16","url":null,"abstract":"<p><p>Viral epidemics develop from the emergence of new variants of infectious viruses. The lack of effective antiviral treatments for the new viral infections coupled with rapid community spread of the infection often result in major human and financial loss. Viral transmissions can occur via close human-to-human contact or via contacting a contaminated surface. Thus, careful disinfection or sanitization is essential to curtail viral spread. A myriad of disinfectants/sanitizing agents/biocidal agents are available that can inactivate viruses, but their effectiveness is dependent upon many factors such as concentration of agent, reaction time, temperature, and organic load. In this work, we review common commercially available disinfectants agents available on the market and evaluate their effectiveness under various application conditions. In addition, this work also seeks to debunk common myths about viral inactivation and highlight new exciting advances in the development of potential sanitizing agents.</p>","PeriodicalId":75305,"journal":{"name":"View (Beijing, China)","volume":"1 2","pages":"e16"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10484442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
